COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick
A Mark
AM
D000075202:Contraindications; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D012449:Safety; D020521:Stroke / Q000139:chemically induced; D013450:Sulfones / Q000009:adverse effects*; D014481:United States
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib